Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
This study is for adults with a blood condition called Polycythemia Vera (PV). Doctors want to learn more about how a specific medicine, ropeginterferon alfa-2b, affects people with PV, especially those who don't have symptoms from a swollen spleen. This isn't a typical drug trial where a new medicine is tested; instead, it's observing how the treatment works for patients in their everyday lives. Researchers will look at how the medicine makes people feel, if it helps to control the condition, and if there are any side effects. They will also collect information about how the treatment is used, such as the doses given, and what influences treatment choices. Overall, the goal is to understand the real-world experience of patients on this medication.
At a glance
What is this study about?
This study is about a blood condition called Polycythemia Vera, or PV for short. In PV, your body makes too many red blood cells. This can sometimes lead to problems like blood clots. The study is specifically looking at a medicine called ropeginterferon alfa-2b, which is already approved for use in PV. This isn't a study where a new, untested drug is being tried out.
Instead, this is more like a 'real-world' observation. Doctors want to understand how people with PV who are taking ropeginterferon alfa-2b are doing in their daily lives. They are particularly interested in patients who don't have a swollen spleen that's causing them symptoms. The main aim is to see how much the treatment helps with everyday symptoms, how well it controls the PV, and if it has any side effects.
By gathering this information, doctors hope to get a clearer picture of the benefits and challenges of using ropeginterferon alfa-2b in regular practice. This will help them understand what factors influence treatment decisions and how the medicine impacts patients' lives over time. It's about learning from the experiences of people actually using the treatment.
Key takeaways
- This study looks at how ropeginterferon alfa-2b works for PV in real life.
- It's for adults with PV who don't have a symptomatic swollen spleen.
- Participation involves sharing information about your symptoms and treatment experience.
- You'll continue your usual medication; no new drugs are given for the study.
- Your input helps doctors understand PV treatment better for all patients.
Who may be eligible?
To join this study, you need to be an adult (18 years or older) and have been diagnosed with Polycythemia Vera (PV). An important point is that you shouldn't have a swollen spleen that's causing you symptoms, as this study is focused on PV patients without this issue.
You also need to be starting or already taking the medicine ropeginterferon alfa-2b, and your doctor must have decided this is the right medication for you based on its official information. If you've already had your first dose, you can still join, but it needs to be within six weeks, and you must still be taking the treatment. You'll also need to be able to complete questionnaires in German.
However, you can't join if you are already taking part in another clinical trial where you're actively receiving treatment. Also, if there are any other reasons why you shouldn't take this specific medication based on its official guidance, then you wouldn't be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Polycythemia Vera (PV)?
- Are you taking (or about to start) ropeginterferon alfa-2b for your PV?
- Do you NOT have a swollen spleen causing you symptoms?
- Are you able to fill out questionnaires in German?
What does participation involve?
If you decide to take part in this study, you'll be giving doctors information about your experience with ropeginterferon alfa-2b in your everyday life. This isn't a study where you'll be given a new medicine or asked to change your treatment plan; you'll already be taking ropeginterferon alfa-2b as prescribed by your doctor.
You'll be asked to fill out questionnaires about how you're feeling and how your symptoms are affecting you. These are called Patient-Reported Outcome (PRO) assessments. Your doctor will also collect information about your health, how the medicine is working for you, any side effects you might experience, and the doses you're taking. The exact number of visits or the total length of your participation isn't specified, but it will involve ongoing check-ups as part of your regular care, where this information will be gathered. You'll sign a consent form to show you understand and agree to take part.
Potential risks and benefits
Locations (1)
- Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der HeydeVerified postcodeHanover, Germany· Recruiting
Common questions
What is Polycythemia Vera (PV)?
PV is an uncommon blood disorder where your body makes too many red blood cells, which can make your blood thicker than normal.
Is ropeginterferon alfa-2b a new medicine?
No, it's an approved medicine for PV. This study is just observing how it works in real-world patients.
Will I have to take different medication if I join?
No, you will continue with your ropeginterferon alfa-2b treatment as prescribed by your doctor. The study just observes this.
Do I need a swollen spleen to join the study?
No, this study is actually for people with PV who do NOT have a swollen spleen causing symptoms.
Can I leave the study at any time?
Yes, you are free to leave the study at any point, and your medical care will not be affected.
How to find out more
Laura Serrer
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.